The European Commission has approved Opuviz 40 mg/mL solution, a biosimilar referencing Eylea, according to a press release from Samsung Bioepis and Biogen.
“Opuviz aims to address key unmet needs in retina care by offering a cost-effective alternative to existing biologics, potentially improving access for patients who may face barriers due to high treatment costs,” a spokesperson for Samsung Bioepis told Healio. “It provides a quality-proven, safe and effective treatment option for managing conditions like neovascular age-related macular degeneration and diabetic macular